Breast Cancer

Online Modules on Breast Cancer

Latest Courses

Evolving and Emerging Trends in HER2 Classification and Reporting in Breast Cancer

The emergence of HER2-low therapies for metastatic breast cancer is a paradigm shift in the traditional binary classification of a patient’s HER2 status, creating a need for practice changes in pathology necessitated by the expansion in how HER2-low breast cancer needs to be classified and treated. During this recorded 2022 ASCP Annual Meeting session, a moderated expert faculty panel discussed evolving and emerging trends in breast cancer classification and reporting across the HER2+ spectrum. They also discussed how pathologists and laboratory professionals can prepare for HER2-low classification, tracking, and reporting. In addition, they reviewed some of the current challenges in HER2 testing and explored opportunities to prepare for the future landscape of HER classification in breast cancer.

Register for Online Course View on YouTube

This activity is supported by educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Ki67 as a Prognostic and Predictive Biomarker in HR-Positive/HER2-Negative Early Breast Cancer

Originally Broadcast January 20, 2022

This 60-minute interactive webinar will feature the expertise of a pathologist and an oncologist highlighting important and practice-changing developments related to the use of Ki67 biomarker testing in patients with HR-positive/HER2-negative early breast cancer, such as new clinical data with immediate implications for patient care. Case-based, and with expert perspectives and recommendations, this webinar addresses key educational gaps and controversies related to optimal Ki67 biomarker testing methods, including challenges with standardization, interpreting findings, and potential therapeutic implications for patients with HR-positive/HER2-negative early breast cancer to optimize clinical outcomes.

Register for Online Course

This activity is supported by an educational grant from Lilly.

Virtual Tumor Board #2: HER2 Testing in Breast Cancer: Improving IHC Performance

Originally Broadcast February 10, 2022

This virtual tumor board from ASCP will help you understand the latest evidence regarding HER2-low breast cancer, HER2 testing guidelines, the implications for the pathology team as HER2-low therapies emerge, and ways to streamline communications with oncologists and other members of the cancer care team.

Register for Online Course View on YouTube

Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC.

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Virtual Tumor Board #1: The Science of HER2-low Breast Cancer and Implications for the Pathology Team

Originally Broadcast January 25, 2022

This virtual tumor board from ASCP will help you understand the science and emerging evidence around HER2-low breast cancer, as well as changes to practice that will be necessary in preparation for anticipated approvals of HER2-low breast cancer therapies.

Register for Online Course View on YouTube

Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC.

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

HER2 Breast Cancer Tweetorials

ASCP is hosting a CME/CMLE-accredited Tweetorial series designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of the latest evidence regarding HER2-low breast cancer and HER2 testing guidelines. Each Tweetorial offers 0.5 CME/CMLE credits.

Tweetorial 1: HER2-low Emerges as a New Classification

This Tweetorial addresses updates from the latest clinical studies on HER2-low breast cancer, HER2-low definition and classification, the clinical implications of HER2-low for the cancer care team, and tools and resources for pathologists.

View Here Claim Credit

Tweetorial 2: Examining the Implications of HER2-low

This Tweetorial covers HER2-low breast cancer, HER2-low classification, the clinical implications of HER2-low for the cancer care team, and tools and resources for pathologists.

View Here Claim Credit

Tweetorial 3: HER2 Intratumoral Heterogeneity

This Tweetorial will cover the following topics: HER2-low breast cancer, HER2-low classification, and HER2 intratumoral heterogeneity.

View Here Claim Credit

Tweetorial 4: HER2 Equivocal and HER2-low

This Tweetorial covers HER2-low breast cancer, HER2-low classification, the clinical implications of HER2-low for the cancer care team, and tools and resources for pathologists.

View Here Claim Credit

Tweetorial 5: Disparities in Care and Updates in HER2-low

This Tweetorial will cover the following topics: disparities in breast cancer care and updates in HER2-low breast cancer.

View Here Claim Credit

Tweetorial 6: Optimizing Communication When HER2 Expression Is Low

This Tweetorial will cover the following topic: ways to optimize communication when HER2 expression levels are low.

View Here Claim Credit

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Provided by the American Society for Clinical Pathology in partnership with Q Synthesis.

Ki67 Testing in Early Breast Cancer Podcast

Ki67 as a Prognostic and Predictive Biomarker in HR-Positive/HER2-Negative Early Breast Cancer Webinar

This podcast from ASCP will highlight important and practice-changing developments related to Ki67 testing, including the standardization, interpretation of findings, and potential therapeutic implications for patients with HR-positive/HER2-negative early breast cancer to optimize clinical outcomes.

Guest panelists:
Sunil S. Badve, MD, FRCPath
Manali Bhave, MD

Listen Now Claim Credit

Provided by the American Society for Clinical Pathology in partnership with Clinical Care Options, LLC.

This activity is supported by an educational grant from Lilly

Access all of ASCP’s Inside the Lab podcasts here.

Resources on Ki67 Testing

These resources, related to a January 2022 ASCP webinar on Ki67 testing, highlight important and practice-changing developments, such as new clinical data with immediate implications for patient care. The resources address key educational gaps and controversies related to optimal testing methods, addressing challenges with standardization, interpreting findings, and potential therapeutic implications for patients with HR-positive/HER2-negative early breast cancer to optimize clinical outcomes.

Access Ki67 Slide Deck

Access Ki67 At-a-Glance Resource

Access Ki67 Expert Commentary

Provided by the American Society for Clinical Pathology in partnership with Clinical Care Options, LLC.

This activity is supported by an educational grant from Lilly

ASCP Pathology Trailblazers in HER2-low Breast Cancer

In 2022, ASCP, working in collaboration with Q Synthesis LLC, invited pathologists to participate in a unique cohort-based leadership development CME program called Pathology Trailblazers: HER2-low Breast Cancer Collaborative Learning Exchange.

This program began in May 2022 and ran for approximately 3 months. Details and findings from the program are below.

Participation Details:

1. Using case studies and facilitated discussion, program faculty guided participants through a leadership framework that outlined how to prepare for the emerging category of HER2-low breast cancer.
2. Participants commited to demonstrating personal leadership growth and development through this program.
3. ASCP held two (2) CME virtual meetings where participants engaged in group dialogue. Each meeting lasted 60 minutes.
4. Participants were able to claim CME credits for completing the program.

To learn more about how the participants implemented their action plans, please view the project summaries below.

Download Project Summary Report

Case-based Microlearning Series: Challenges in Testing Across the HER2+ Breast Cancer Spectrum

This CME/CMLE-accredited, case-based microlearning activity is designed to help pathologists and laboratory professionals increase their knowledge, skills, and competence in testing and diagnosing breast cancer across the HER2 spectrum.

Every few days, participants will be emailed or sent several questions through the Qstream app. Each question consists of an authentic patient case/scenario and an assessment question with 3-5 multiple-choice answers designed to help you make an appropriate diagnosis/recommendation.

This case-based microlearning activity includes the following topics:

• Best practices in IHC interpretation across the HER2 spectrum
• Clinical practice guidelines for IHC and ISH testing
• The science and emerging evidence around HER2-low breast cancer
• HER2 classification, tracking, and reporting considerations
• Emerging treatment options for patients with HER2-low breast cancer
• The critical importance of communication within the multidisciplinary cancer care team

The activity offers 1.0 CME/CMLE credit.

Learning Objectives

Upon completion of this activity, you should be able to:

• Appropriately conduct IHC and ISH testing, classification, and reporting in routine and complex breast cancer cases across the HER2 spectrum in accordance with guidelines
• Describe the science and emerging evidence around the diagnosis, testing, and treatment of patients with HER2-low breast cancer
• Update laboratory processes and procedures (e.g., related to identification, tracking, and reporting) to prepare for the anticipated emergence of HER2-low as a diagnostic category of breast cancer
• Outline ways to improve communication and coordination among pathologists, oncologists, and other members of the cancer care team when discussing HER2 test results in patients with breast cancer

Faculty

Swikrity U. Baskota, MD
Assistant Professor of Pathology and Cell Biology
Columbia University Medical Center

Poonam Vohra, MD, FASCP
Associate Professor, Anatomic Pathology
University of California, San Francisco

Faculty Disclosures

Swikrity U. Baskota, MD, and Poonam Vohra, MD, FASCP, have no relevant financial relationships to disclose.